Evidence map›Paper›PMID 41626535›Full record

ArticleJTO clinical and research reports2026

Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA).

Grace Chazan, Marliese Alexander, Fanny Franchini, Maarten IJzerman, Roma Shah, Ani John, Tim Spelman, Malinda Itchins, Nick Pavlakis, Adnan Nagrial and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Grace ChazanSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Marliese AlexanderSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Fanny FranchiniCancer Health Services Research Unit, Collaborative Centre for Genomic Cancer Medicine, University of Melbourne, Parkville, Victoria, Australia.
Maarten IJzermanCancer Health Services Research Unit, Collaborative Centre for Genomic Cancer Medicine, University of Melbourne, Parkville, Victoria, Australia.
Roma ShahRoche Diagnostics, Santa Clara, California.
Ani JohnRoche Diagnostics, Santa Clara, California.
Tim SpelmanCentre for Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
Malinda ItchinsRoyal North Shore Hospital, Sydney University, New South Wales, Australia.
Nick PavlakisRoyal North Shore Hospital, Sydney University, New South Wales, Australia.
Adnan NagrialWestmead Hospital, Sydney, New South Wales, Australia.
Lydia WarburtonFiona Stanley Hospital, Perth, Western Australia, Australia.
Samantha BowyerSir Charles Gairdner Hospital, Perth, Western Australia, Australia.
Steven KaoChris O'Brien Lifehouse, Sydney, New South Wales, Australia.
Sagun ParakhAustin Hospital, Melbourne, Victoria, Australia.
Benjamin J SolomonSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Advanced lung cancer has historically been associated with poor survival. However, with the advent of targeted therapies, outcomes are improving. Among patients with Methods: We conducted a retrospective observational cohort study using deidentified patient, disease, and outcomes data from the AUstralasian thoRacic cancers lOngitudinal cohoRt study and biobAnk (AURORA; ACTRN12625000038493). Eligible patients were diagnosed with ALK+ aNSCLC between 2006 and 2025. Results: Of the 4776 patients with thoracic malignancies enrolled across eight sites (as of April 2025), 218 met the inclusion criteria-the largest reported Australian cohort of ALK+ aNSCLC. All patients were treated in academic centers. The median age was 55 years; 54% were female, 66% were never-smokers, and 41% had participated in a clinical trial. The median overall survival was 90.8 months (95% CI: 69.8-not reached). Nearly all patients (99%) received an ALK inhibitor; 83% in the first-line setting. Treatment sequences evolved over time. Most (68%) received at least two lines of therapy; 21% received 4 or more lines. Smoking status, age, and Eastern Cooperative Oncology Group Performance Status were prognostically associated with survival. Conclusion: This study highlights the remarkable survival achievable in the real-world setting for some patients with ALK+ aNSCLC, compared with historical cohorts. Several clinical factors associated with survival were identified. Larger studies are needed to investigate how treatment sequences may be optimized to further improve survival outcomes.

Indexed as

ALK+ lung cancerPrognostic factorsReal-worldTreatment sequence

Identifiers

PMID41626535
PMCPMC12856545

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.